A prospective observational study was conducted consisting of 21 patients of Juvenile-onset recurrent respiratory papillomatosis, attending the Department of Otorhinolaryngology and Head Neck Surgery at our institution, who underwent surgical excision of the papillomas followed by oral acyclovir postoperatively. The study was aimed to observe the effect of systemic acyclovir on postoperative outcomes in children having recurrent respiratory papillomatosis undergoing primary surgical excision. It was observed that the mean interval between surgeries as well as the number of surgical interventions required was significantly lesser when acyclovir was used as a postoperative adjuvant than when surgery was done alone. Hence, the interval between successive surgeries, or in other words, the time interval between relapse of the disease could be prolonged significantly with the use of postoperative systemic acyclovir. Thus, the disease could be controlled for longer periods and repeated surgeries avoided.
Introduction
Recurrent respiratory papillomatosis (RRP) is a benign disease of infective etiology affecting the respiratory tract. The infective organism is a double-stranded DNA virus named human papilloma virus (HPV). The most commonly associated serotypes include HPV 6 and 11. 1 Depending on the age of presentation, RRP can be classified into 2 types-Juvenile-onset RRP (JORRP) and adult-onset RRP. Juvenile-onset RRP is defined by an age of onset less than 12 years. 2 The common presenting symptoms are voice change, respiratory distress, and chronic cough. Surgical excision of the papillomas remains the mainstay of treatment. However, the disease is notorious for relapse, and the patients often need to undergo repeated surgeries within short intervals of time. This amounts to greater morbidity, financial burden, and significantly affects the quality of life.
Acyclovir is a DNA polymerase inhibitor and hence effective against DNA encoded viruses. This study is aimed to observe the effect of oral acyclovir on the postoperative outcome following endolaryngeal excision of the respiratory papillomas.
Patients and Methods
We conducted a prospective observational study comprising of 21 patients with JORRP attending the Department of Otorhinolaryngology and Head Neck Surgery of our institution. Patient less than 12 years of age with a history of at least 2 previous endolaryngeal surgeries within 4 months span and histopathologically consistent with papillomatosis were included in our study. None of the patients were known to have any other systemic illness or received acyclovir, in any form, prior to participation in this study. The guardians were explained about the surgical procedure in detail. Written informed consent and institutional ethical clearance (Memo No. IPGME&R/IEC/2018/570) regarding postoperative use of acyclovir were obtained. The patients underwent surgical excision of the papillomas using microdebrider (Medtronic IPC). The next day, the patients were started on oral acyclovir at a dose of 80 mg/kg/d in divided doses (max 3200 mg/d). The oral antiviral regimen was continued for 2 months postoperatively. Biochemical parameters, most importantly, the renal function profile was closely monitored for toxicity, on a monthly basis apart from routine blood count. The patients were followed up for a period of 1 year after surgery plus acyclovir therapy.
Results
Data were summarized as mean and standard deviation for continuous and median and interquartile range for ordinal variables and counts and percentages for categorical variables. Paired t test was done for paired samples that are normally distributed. Wilcoxon signed-rank test was used for paired samples that are non-normally distributed. P value .05 was considered to be statistically significant.
Fifteen (71.4%) patients belonged to 5 years age-group and 6 (28.6%) patients were >5 years old. The mean of interval between surgeries (mean [SD]) was 2.8 (0.9) months before acyclovir therapy was used as an adjuvant. The mean of interval between surgeries (mean [SD]) was 4 (1.7) months after acyclovir was added (Figure 1 ). Difference in mean interval between surgeries in 2 groups was statistically significant (P ¼ .0410). The median number of surgical interventions was 3 (range: 2-10) before acyclovir therapy. The median number of surgical interventions was 1 (range: 0-6) after acyclovir therapy (Figure 2 ). Difference in number of surgical interventions in 2 groups was statistically significant (P < .05; Table 1 ). The mean interval of symptom-free period since last surgery with acyclovir as an adjuvant (mean [SD]) was 13.5 (6.4) months (Table 2) .
Discussion
Recurrent respiratory papillomatosis, in spite of being a benign disease, often assumes an aggressive course. Infection with HPV11 typically produces such a clinical picture. 3 The virus is believed to spread by vertical transmission from mother to child during the process of childbirth. Presence of genital condylomas in the mother and a history of prolonged labor increases the risk of JORRP in the child. 4 In this respect, quadrivalent vaccination against HPV(Gardasil) has been used. In a recent study conducted in Australia, there is documented decline in the incidence of JORRP following mass vaccination. 5 The same has been reported to cause remission when used in 2 cases of aggressive JORRP. 6, 7 Children requiring more than 4 surgical interventions in one year or disease extending outside the larynx are known to harbor the aggressive form of JORRP. 8 With such forms of disease, the patients often need to go through numerous debulking procedures to alleviate symptoms. Apart from affection by the disease process itself, repeated surgical insults to the growing respiratory epithelium is detrimental to the quality of voice. This has a profound psychosocial impact on the patients of this age-group as well as on their parents. Keeping this in mind, there has been a paradigm shift toward surgical procedures that preserve voice quality as far as possible. Light Amplification by Stimulated Emission of Radiation (LASER) in the form of CO 2 or KTP has been used for removal or debulking of laryngeal papillomas. However, they do cause thermocoagulative damage to the underlying laryngeal tissues. 9 Microdebrider, on the other hand, is not associated with any adverse thermal injury. With the advent of more sophisticated skimmer laryngeal blade (Medtronic, Jacksonville, Florida), it is possible to address the disease in a much gentle and faster way, and at the same time avoid the adversities of LASER. But no surgical technique is perfect and each procedure adds to some amount of scarring (Figure 3) . Hence, repeated procedures are detrimental to pediatric voice. Herein comes the role of adjunctive therapies which reduce the number of surgeries and prolong the disease-free periods in between (Figure 4) . A number of adjuvant therapies have been used in RRP. Antiviral agents include systemic acyclovir, ribavirin, and intralesional cidofovir. McGlennen et al used ribavirin in 3 adult patients and 1 infant with respiratory papillomatosis. Ribavirin is known to cause anemia and reticulocytosis. 10 Cidofovir is a broad-spectrum antiviral agent that has been used as intralesional injection following surgical debulking. Cidofovir has showed promising results but carries the risk of significant nephrotoxicity and carcinogenic potential in animal models. 11, 12 Acyclovir is a viral DNA polymerase inhibitor commonly used to treat varicella infection. The drug can be safely used in children even on long-term use. Long-term acyclovir therapy has been used in neonatal herpes for a duration of 6 months and in ocular herpes infection for 1 year. 13, 14 Gastrointestinal side effects and headache are the reported complications when used for prolonged duration. 15 Hence, acyclovir is a safe, readily available antiviral agent that may be combined with surgery as an adjuvant for treating this potentially aggressive disease. 
Conclusion
Even a single surgical manipulation of the delicate pediatric larynx may lead to scarring and adverse voice outcome postoperatively. Juvenile-onset RRP is a disease of relapse and recurrences requiring multiple surgical interventions. Thus, surgery combined with acyclovir may avoid the need of repeated surgeries by prolonging the symptom-free periods, enabling us to preserve the voice which is of paramount importance in a growing child.
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